366 related articles for article (PubMed ID: 14613552)
1. Animal models of ovarian cancer.
Vanderhyden BC; Shaw TJ; Ethier JF
Reprod Biol Endocrinol; 2003 Oct; 1():67. PubMed ID: 14613552
[TBL] [Abstract][Full Text] [Related]
2. Models of ovarian cancer--are we there yet?
Garson K; Shaw TJ; Clark KV; Yao DS; Vanderhyden BC
Mol Cell Endocrinol; 2005 Jul; 239(1-2):15-26. PubMed ID: 15955618
[TBL] [Abstract][Full Text] [Related]
3. Early events in ovarian oncogenesis.
Cvetkovic D
Reprod Biol Endocrinol; 2003 Oct; 1():68. PubMed ID: 14577833
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis.
Okamura H; Katabuchi H
Int Rev Cytol; 2005; 242():1-54. PubMed ID: 15598466
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer.
Greenaway J; Moorehead R; Shaw P; Petrik J
Gynecol Oncol; 2008 Feb; 108(2):385-94. PubMed ID: 18036641
[TBL] [Abstract][Full Text] [Related]
6. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation.
Salceda S; Tang T; Kmet M; Munteanu A; Ghosh M; Macina R; Liu W; Pilkington G; Papkoff J
Exp Cell Res; 2005 May; 306(1):128-41. PubMed ID: 15878339
[TBL] [Abstract][Full Text] [Related]
7. Structural changes and cell properties of human ovarian surface epithelium in ovarian pathophysiology.
Okamura H; Katabuchi H; Nitta M; Ohtake H
Microsc Res Tech; 2006 Jun; 69(6):469-81. PubMed ID: 16718660
[TBL] [Abstract][Full Text] [Related]
8. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses.
Fleming JS; Beaugié CR; Haviv I; Chenevix-Trench G; Tan OL
Mol Cell Endocrinol; 2006 Mar; 247(1-2):4-21. PubMed ID: 16297528
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm.
Ahmed N; Thompson EW; Quinn MA
J Cell Physiol; 2007 Dec; 213(3):581-8. PubMed ID: 17708542
[TBL] [Abstract][Full Text] [Related]
10. Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer.
Rancourt C; Bergeron C; Lane D; Garon G; Piché A
Cytotherapy; 2003; 5(6):509-22. PubMed ID: 14660047
[TBL] [Abstract][Full Text] [Related]
11. The ovarian surface epithelium: simple source of a complex disease.
Choi KC; Auersperg N
Minerva Ginecol; 2003 Aug; 55(4):297-314. PubMed ID: 14581855
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer.
Chien JR; Aletti G; Bell DA; Keeney GL; Shridhar V; Hartmann LC
J Cell Biochem; 2007 Dec; 102(5):1117-29. PubMed ID: 17879946
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer.
Janát-Amsbury MM; Yockman JW; Anderson ML; Kieback DG; Kim SW
Anticancer Res; 2006; 26(4B):2785-9. PubMed ID: 16886597
[TBL] [Abstract][Full Text] [Related]
14. Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer.
Popadiuk CM; Xiong J; Wells MG; Andrews PG; Dankwa K; Hirasawa K; Lake BB; Kao KR
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2216-23. PubMed ID: 16609037
[TBL] [Abstract][Full Text] [Related]
15. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.
Isayeva T; Ren C; Ponnazhagan S
Clin Cancer Res; 2005 Feb; 11(3):1342-7. PubMed ID: 15709207
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
17. Animal models of ovarian cancer.
Connolly DC
Cancer Treat Res; 2009; 149():353-91. PubMed ID: 19763445
[No Abstract] [Full Text] [Related]
18. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer.
Brewer M; Wharton JT; Wang J; McWatters A; Auersperg N; Gershenson D; Bast R; Zou C
Gynecol Oncol; 2005 Aug; 98(2):182-92. PubMed ID: 15907982
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia.
Stewart SL; Querec TD; Ochman AR; Gruver BN; Bao R; Babb JS; Wong TS; Koutroukides T; Pinnola AD; Klein-Szanto A; Hamilton TC; Patriotis C
Cancer Res; 2004 Nov; 64(22):8177-83. PubMed ID: 15548682
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated calponin h1 gene therapy directed against peritoneal dissemination of ovarian cancer: bifunctional therapeutic effects on peritoneal cell layer and cancer cells.
Ogura T; Kobayashi H; Ueoka Y; Okugawa K; Kato K; Hirakawa T; Hashimoto S; Taniguchi S; Wake N; Nakano H
Clin Cancer Res; 2006 Sep; 12(17):5216-23. PubMed ID: 16951241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
